関連する実験動画
Updated: Aug 10, 2026
08:59
Defining Substrate Specificities for Lipase and Phospholipase Candidates
Published on: November 23, 2016
高密度リポプロテインの内皮リパースによる高密度リポプロテインの分解の用量依存加速
Cyrille Maugeais1, Uwe J F Tietge, Uli C Broedl
1Departments of Medicine, University of Pennsylvania, Philadelphia, Pa, USA.
Circulation
|October 1, 2003
まとめ
ネズミの内皮リンパゼ (EL) の過剰発現は,血のリンパゼ活性とHDLの分解を増加させる. これは,腎臓と肝臓での吸収を増やすことにより,HDLコレステロールとアポリポプロテインA-Iレベルを低下させます.
科学分野:
- 脂質代謝 脂質代謝とは
- 心血管研究に関する研究.
- バイオケミストリー バイオケミストリー
背景:
- 高密度リポプロテイン (HDL) とアポリポプロテインA-I (apoA-I) の代謝を調節するメカニズムは完全に理解されていません.
- ネズミの内皮脂酶 (EL) の過剰発現は,HDLコレステロールとapoA-Iレベルを著しく低下させるが,その根本的な理由は不明である.
研究 の 目的:
- ネズミのHDL代謝に対する内皮脂酶 (EL) 過剰発現の影響を調査する.
- ELがHDLコレステロールとapoA-Iレベルに影響を与えるメカニズムを解明する.
主な方法:
- リコンビナントアデノウイルスベクトルを使用したマウスにおけるヒトELの過剰発現.
- 評価されたプラズマフォスフォリファーゼ活性,脂質プロファイル,HDL粒子のサイズ,HDLターンオーバー運動,およびアポA-Iの組織吸収.
主要な成果:
- EL過剰発現は,投与量に依存したポステパリン後のプラズマフォスホリファーゼの活性が増加した.
- プラズマフォスフォリピド,HDLコレステロール,およびapoA-Iの有意な減少が観察されました.
- HDL-アポリポプロテインの分数分解率の増加と腎臓と肝臓によるアポA-Iの吸収の増加が認められた.
結論:
- ネズミのEL発現は,血のフォスフォリファーゼ活性とHDL分解を高めます.
- これにより,HDLコレステロールとapoA-Iレベルが低下します.
- カタボリズムの増加は,腎臓と肝臓でアポA-Iの吸収が強化されたことに起因する.
関連する概念動画
01:38Receptor-mediated Endocytosis
Overview
01:06Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...